EICHOR
● Completed
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
Condition: Metastatic Castration Resistant Prostate Cancer · Sponsor: pharmaand GmbH
About this study
The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (150)
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Mayo Clinic - Arizona | Phoenix, Arizona, United States | — |
| Arizona Oncology Associates - USOR | Tucson, Arizona, United States | — |
| University of Southern California | Beverly Hills, California, United States | — |
| Alliance Research Centers | Laguna Hills, California, United States | — |
| VA Greater Los Angeles Healthcare System | Los Angeles, California, United States | — |
| San Bernardino Urological Associates | San Bernardino, California, United States | — |
| Sharp Memorial Hospital | San Diego, California, United States | — |
| Pacific Hematology Oncology Associates | San Francisco, California, United States | — |
| San Francisco VA Health Care System | San Francisco, California, United States | — |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | — |
| St. Joseph Heritage Healthcare | Santa Rosa, California, United States | — |
+ 138 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02975934